Revaccination With Pollinex® Quattro
Revaccination With Pollinex® Quattro
The purpose of this non interventional study (NIS) was to observe the efficacy of Pollinex®
 Quattro as a short-term revaccination in patients who have already been successfully
 desensitized at least five years ago against grass-pollen but developed a recurrent allergy.
The increasing prevalence of allergies represents a major problem for the health care system.
 Approximately 500 million people are suffering worldwide from allergic rhinitis (AR).
 Allergic rhinitis is a Type 1 hypersensitive disorder, initiated by IgE antibodies. Whereas
 seasonal allergic rhinitis (SAR) is caused by different allergens found outdoors such as
 grass, tree and weed pollen, perennial allergic rhinitis (PAR) is caused by allergens that
 are mainly found indoors such as dust mites, mould or animal hair.

 Specific immunotherapy (SIT) presently constitutes the only causal therapy available and is
 common practice. SIT is indicated in cases of IgE-mediated allergic diseases and includes two
 forms of treatment options: subcutaneous (SCIT) and sublingual immunotherapy (SLIT). Both
 therapies aim to train the immune system not react to supposed pathological allergens, but
 instead to develop tolerance to them.

 Even though allergy vaccinations have been applied for a century, the commonly used SCIT
 requires up to 90 injections over three to five years. Pollinex® Quattro is currently the
 only ultra-short term medicinal product which requires only four preseasonal injections. The
 immunological effect associated with Pollinex® Quattro shows an increase of allergen-specific
 IgG antibodies and a decrease of allergen-specific IgE antibodies as well as a shift from a
 Th2 to a more Th1 type-immune reaction. Previous studies on the therapeutic efficacy of
 Pollinex® Quattro have come to a positive conclusion in regards to tolerability and decrease
 of allergic symptoms. As an ultra-short course SCIT, Pollinex® Quattro might decrease the
 number of noncompliance and withdrawal for revaccination in patients that have already
 undergone an intensive immunisation therapy.

 In this non-interventional study, patients who were treated with Pollinex® Quattro and
 patients who decided to use anti-allergic drugs for the treatment of their grass pollen
 allergy were compared due to their allergic symptoms in the grass pollen season from May to
 July. For this purpose, the rhinoconjunctivitis and asthmatic symptoms as well as the use of
 concomitant medication were documented in a dia
Inclusion Criteria:

 -  Adults and children from the age of 12 years on, who are diagnosed with recurrent
 seasonal allergic rhinitis (SAR) caused by grass pollen.

 A previous specific immunotherapy finished at least five years ago had to be successful.

 Exclusion Criteria:

 -  Contraindications according to the patient information leaflet